Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Benjamin Philip Levy, MD, offers opinion on testing for PD-L1 expression in NSCLC

Dr. Levy elaborates on whether every non-small cell lung cancer (NSCLC) patient should be tested for PD-L1 expression and what levels of PD-L1 expression are actionable

Published: 27 June 2018

Recent Videos

video

Rana McKay, MD, explains how to differentiate between TKIs available for renal cell cancer patients

Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, describes how to differentiate between the various ...

video

Rana McKay, MD, on next steps when treating mRCC patients who receive I-O in the front line space

Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, considers how to treat patients with metastatic ...

video

William Oh, MD, discusses the evolving treatment landscape for patients with nmCRPC

Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, elaborates on the scope of unmet need for ...

video

Rana McKay, MD, offers impressions of the TIVO-3 study in highly refractory advanced RCC patients

Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, shares thoughts on the outcomes from the ...

video

William Oh, MD, tells us how PSA is valuable as a biomarker in the treatment of prostate cancer

Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, considers how prostate-specific antigen (PSA) is most valuable ...

video

Rana McKay, MD, on recent data examining atezolizumab and bevacizumab in nccRCC & sccRCC

Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, offers opinion on whether the results of ...

video

William Oh, MD, discusses recent data examining LuPSMA in men with mCRPC

Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, shares outcomes of the study presented at the ...

video

Rana McKay, MD, considers the implications of CHECKMATE 214 & KEYNOTE-426 presented at GU 2019

Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, on whether the results of KEYNOTE-426 and ...

video

William Oh, MD, regarding data on racial differences in response to novel prostate cancer therapies

Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, summarizes the large retrospective trial presented the 2019 ...

video

Rana McKay, MD, elaborates on the outcomes of the KEYNOTE 426 Phase III study in mRCC

Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, shares outcomes of the KEYNOTE 426 Phase ...

Related Videos

video-image

William Oh, MD, discusses the evolving treatment landscape for patients with nmCRPC

video-image

Rana McKay, MD, on next steps when treating mRCC patients who receive I-O in the front line space

video-image

Rana McKay, MD, explains how to differentiate between TKIs available for renal cell cancer patients

video-image

William Oh, MD, discusses recent data examining LuPSMA in men with mCRPC

video-image

Rana McKay, MD, on recent data examining atezolizumab and bevacizumab in nccRCC & sccRCC

video-image

William Oh, MD, tells us how PSA is valuable as a biomarker in the treatment of prostate cancer

video-image

Rana McKay, MD, offers impressions of the TIVO-3 study in highly refractory advanced RCC patients

video-image

Yair Lotan, MD, on the challenges using biomarkers for treatment selection in bladder cancer

video-image

Andrew Armstrong, MD, presents an overview of the ARCHES trial in mHSPC

video-image

Mark T. Fleming, MD, regarding the implications of the CHECKMATE 650 study presented at GU 2019

video-image

Michael Atkins, MD, regarding the KEYNOTE 426 Phase III trial in metastatic renal cell carcinoma

video-image

Yair Lotan, MD, shares outcomes of KEYNOTE 057 in high-risk non-muscle-invasive bladder cancer

video-image

Andrew Armstrong, MD, discusses the Phase 2 STREAM study in pre-metastatic prostate cancer

video-image

Yair Lotan, MD, considers the role of checkpoint inhibitors in bladder cancer

video-image

Michael Atkins, MD, offers opinion on IO-TKI combinations in renal cell cancer

video-image

Rana McKay, MD, elaborates on the outcomes of the KEYNOTE 426 Phase III study in mRCC

video-image

Andrew Armstrong, MD, offers opinion on androgen receptor inhibitors

video-image

William Oh, MD, regarding data on racial differences in response to novel prostate cancer therapies

video-image

Mark T. Fleming, MD, on the ARCHES trial in metastatic hormone-sensitive prostate cancer

video-image

Rana McKay, MD, considers the implications of CHECKMATE 214 & KEYNOTE-426 presented at GU 2019